07:00 , Oct 6, 2014 |  BioCentury  |  Finance

Atlas' next chapter

After separating from the tech group, Atlas Venture 's healthcare team plans to stick to the early stage investing strategy the firm says has provided returns in the top quartile of life science VCs. For...
07:00 , Aug 22, 2011 |  BC Week In Review  |  Company News

BAC B.V., Bristol-Myers deal

BAC will generate CaptureSelect custom affinity ligands for purification and analysis of Bristol-Myers’ Adnectin compounds. Adnectins are proteins derived from fibronectin, an extracellular protein in human serum. Bristol-Myers gained rights to the compounds through its...
07:00 , Aug 1, 2011 |  BioCentury  |  Strategy

Therapeutically adjacent

Bristol-Myers Squibb Co. 's acquisition of Amira Pharmaceuticals Inc. appears at first blush to net a single compound that has completed Phase I testing in a completely new disease area for the pharma, along with...
07:00 , May 23, 2011 |  BioCentury  |  Finance

Strategic value trumps IPO

On the eve of Advanced BioHealing Inc. 's NYSE debut last week, Shire plc (LSE:SHP; NASDAQ:SHPGY) said it would acquire the company for $750 million in cash, making it the first biotech in almost four...
08:00 , Feb 21, 2011 |  BioCentury  |  Strategy

Sweet Spot revisited

Another biotechnology pioneer is being swept away by an innovation-starved big pharmaceutical company, the latest reflection of the bleak outlook of a biopharma industry blanketed by R&D failures, hostile regulators, unwilling payers and the flight...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Civitas management update

Civitas Therapeutics Inc. , Chelsea, Mass.   Business: Drug delivery, Neurology, Pulmonary   Hired: Glenn Batchelder, co-founder, as CEO; Richard Batycky as CSO; and Martin Freed as CMO; all of whom formerly served in the...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Eleven Biotherapeutics management update

Eleven Biotherapeutics Inc. , Cambridge, Mass.   Business: Inflammation, Hematology, Musculoskeletal   Hired: Eric Furfine as president of R&D, formerly SVP of research and preclinical development at Adnexus Therapeutics Inc. , which was acquired by...
08:00 , Jan 17, 2011 |  BioCentury  |  Product Development

Middle class values

For the past year and a half, Bristol-Myers Squibb Co. has quietly in-licensed libraries of compounds that are able to interrogate protein-protein interactions within cells. The key to accessing these previously intractable targets, according to...
02:24 , Jan 11, 2011 |  BC Extra  |  Financial News

Alkermes spinout launches with $20 million

Civitas Therapeutics Inc. (Chelsea, Mass.) raised $20 million in a series A round led by Longitude Capital Management and Canaan Partners. Civitas is a spinout of the pulmonary delivery business of Alkermes Inc. (NASDAQ:ALKS). Civitas'...
07:00 , May 31, 2010 |  BC Week In Review  |  Company News

aTyr board of directors update

aTyr Pharma Inc. , San Diego, Calif.   Business: Hematology, Inflammation, Cancer   Appointed: John Mendlein as executive chairman, currently chairman of Fate Therapeutics Inc. and Alevium Pharmaceuticals, previously CEO of Adnexus Therapeutics Inc.  ...